Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Marc Bourgault who wrote (4327)	5/18/1998 7:25:00 PM
From: PAL	Read Replies (2) \| Respond to of 6136

We are just noticing that Ms Wang's recommendation carries as much weight as yours and mine. I thought that AGPH will present its findings of AG3340 to the LA conference. AGPH is much further than ENMD yet that small biotech company could ride on the coattail of Genentech, while AGPH is heading south. To quote that famous Mr. Henry Lee: "something is wrong here". AGPH management should realize that stockholders invest in the company for the return on investment. If the horse is a dud, then people will get a different horse. Good Luck to every and all AGPH stockholders. PAL

To: Marc Bourgault who wrote (4327)	5/18/1998 7:28:00 PM
From: Steve Fancy	Read Replies (2) \| Respond to of 6136

Marc, I don't believe I'm hitting Ms Wang. I only stated the facts as I see them. If the stock is annnnywhere close to her price target a year from say the last earnings report (have to pick a point in time somewhere) I'll have much greater respect for her. In the meantime, she certainly stands in a league all her own with her price target. I believe the $45 - $51 range suggested by other analysts is much more realistic, and in reality, a reasonable gain from where we're at. I was only suggesting that her unbending price target established for so long, was likely the reason she doesn't seem to command a lot of influence over the market. sf